Happy World Obesity Day 2026! Today, March 4th, we join the global movement under the theme "8 Billion Reasons to Act on Obesity." At Dermacode by Dr. Parth, we believe that managing weight isn't just about "willpower"—it’s about using the right medical tools to support your biology. Whether you are looking to kickstart your weight loss journey or refine your physique, we offer a comprehensive, 360-degree approach to body transformation. Here is how we can help you change your story: 1. Medical Weight Loss: Mounjaro & Ozempic For many, the struggle with weight is rooted in metabolic health. We offer the latest in FDA-approved injectable therapies: • Mounjaro (Tirzepatide): A revolutionary "dual agonist" that targets two hunger hormones (GLP-1 and GIP), offering some of the highest weight loss percentages seen in clinical history. • Ozempic (Semaglutide): The gold standard for regulating appetite and blood sugar, helping you feel fuller for longer and reducing cravings effectively. 2. Emshape: The Future of Body Contouring Losing weight is a win, but building definition is the goal. Emshape is our non-invasive solution for those who want to tone up without the gym burnout. • How it works: It uses HIFEM (High-Intensity Focused Electromagnetic) technology to trigger 20, 000+ supramaximal muscle contractions in a 30-minute session. • The Result: Simultaneous fat reduction and muscle building for the abdomen, buttocks, and arms. 3. Deoxycholic Acid: Say Goodbye to the Double Chin Stubborn fat under the chin often resists even the strictest diets. Our Deoxycholic Acid injections (popularly known as Kybella) target submental fat directly. • Targeted Fat Loss: This naturally occurring molecule breaks down fat cells permanently. • Profile Refinement: Achieve a sharper jawline and eliminate the "double chin" with a series of quick, minimally invasive injections. Why Choose Dermacode by Dr. Parth? Under the expert guidance of Dr. Parth, every treatment plan is customized. We don't just treat the scale; we treat the individual.